BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 32096197)

  • 1. Arsenic trioxide-eluting Callispheres beads is more effective and equally tolerant compared with arsenic trioxide/lipiodol emulsion in the transcatheter arterial chemoembolization treatment for unresectable hepatocellular carcinoma patients.
    Duan XH; Ju SG; Han XW; Ren JZ; Li FY; Chen PF; Wu YY; Li H
    Eur Rev Med Pharmacol Sci; 2020 Feb; 24(3):1468-1480. PubMed ID: 32096197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcatheter arterial chemoembolization using CalliSpheres beads loaded with arsenic trioxide for unresectable large or huge hepatocellular carcinoma: a prospective study.
    Duan X; Li H; Chen P; Sun T; Kuang D; Lu H; Qiao B; Fan Z; Ren Z; Han X
    Eur Radiol; 2024 Feb; 34(2):1258-1267. PubMed ID: 37581654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
    Wu B; Zhou J; Ling G; Zhu D; Long Q
    World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of treatment response, survival and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres® microspheres versus conventional transarterial chemoembolization in treating hepatocellular carcinoma.
    Zhao C; Ma SPZCY
    J BUON; 2019; 24(3):1150-1166. PubMed ID: 31424674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety.
    Zhang ZS; Li HZ; Ma C; Xiao YD
    BMC Cancer; 2019 Nov; 19(1):1162. PubMed ID: 31783814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
    Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
    Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
    [No Abstract]   [Full Text] [Related]  

  • 7. CalliSpheres Drug-Eluting Bead Transcatheter Arterial Chemoembolization Presents With Better Efficacy and Equal Safety Compared to Conventional TACE in Treating Patients With Hepatocellular Carcinoma.
    Xiang H; Long L; Yao Y; Fang Z; Zhang Z; Zhang Y
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819830751. PubMed ID: 30862264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
    Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
    BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of transcatheter arterial chemoembolization with embospheres in treatment of hepatocellular carcinoma.
    Hao MZ; Lin HL; Chen QZ; Hu YB; Chen JB; Zheng JX; Zhou D; Zhang H
    J Dig Dis; 2017 Jan; 18(1):31-39. PubMed ID: 27987344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
    Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
    AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis.
    Shi Q; Liu J; Li T; Zhou C; Wang Y; Huang S; Yang C; Chen Y; Xiong B
    Clin Res Hepatol Gastroenterol; 2022 May; 46(5):101893. PubMed ID: 35247625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history: A comparison of efficacy and safety.
    Li H; Wu F; Duan M; Zhang G
    Medicine (Baltimore); 2019 May; 98(21):e15314. PubMed ID: 31124925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic Arterial Chemoembolization With Arsenic Trioxide Eluting CalliSpheres Microspheres Versus Lipiodol Emulsion: Pharmacokinetics And Intratumoral Concentration In A Rabbit Liver Tumor Model.
    Duan XH; Li H; Ren JZ; Han XW; Chen PF; Li FY; Huang GH; Ju SG
    Cancer Manag Res; 2019; 11():9979-9988. PubMed ID: 32063723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Callispheres® drug-eluting beads transarterial chemoembolization might be an efficient and safety down-staging therapy in unresectable liver cancer patients.
    Peng N; Mao L; Tao Y; Xiao K; Yuan G; He S
    World J Surg Oncol; 2022 Aug; 20(1):254. PubMed ID: 35941634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
    BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of chemoembolization with CalliSpheres
    Liang B; Xiang H; Ma C; Xiong B; Ma Y; Zhao C; Yao Y; Zhang Z; Chen C; Li H; Long Q; Zhou J; Luo C; Qiu H; Hu H; Zhao H; Zhou G; Zheng C
    Cancer Manag Res; 2020; 12():941-956. PubMed ID: 32104076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of CalliSpheres
    Shi Z; Wang D; Kang T; Yi R; Cui L; Jiang H
    Radiol Oncol; 2023 Mar; 57(1):70-79. PubMed ID: 36794998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of treatment efficacy and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres
    Ma Y; Zhao C; Zhao H; Li H; Chen C; Xiang H; Zheng C; Ma C; Luo C; Qiu H; Yao Y; Hu H; Xiong B; Zhou J; Zhu H; Long Q
    Am J Transl Res; 2019; 11(12):7456-7470. PubMed ID: 31934293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history.
    Tang J; Huang Z; Xu J; Lv Q; Wang P
    Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101814. PubMed ID: 34597848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety profile of drug-eluting beads transarterial chemoembolization by CalliSpheres® beads in Chinese hepatocellular carcinoma patients.
    Zhou GH; Han J; Sun JH; Zhang YL; Zhou TY; Nie CH; Zhu TY; Chen SQ; Wang BQ; Yu ZN; Wang HL; Chen LM; Wang WL; Zheng SS
    BMC Cancer; 2018 Jun; 18(1):644. PubMed ID: 29914435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.